Enjoy complimentary customisation on priority with our Enterprise License!
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 08: Parent market
*Exhibit 09: Market characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis: Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
*2.2.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 11: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 12: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2020 - 2025 ($ million)
*Exhibit 14: Global market: Year-over-year growth 2020 - 2025 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2020 & 2025
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2020
***5 Market Segmentation by Product
**5.1 Market segments
*Exhibit 22: Product - Market share 2020-2025 (%)
**5.2 Comparison by Product
*Exhibit 23: Comparison by Product
**5.3 Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025
*Exhibit 24: Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)
*Exhibit 25: Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)
**5.4 SNRIs and TCAs - Market size and forecast 2020-2025
*Exhibit 26: SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)
*Exhibit 27: SNRIs and TCAs - Year-over-year growth 2020-2025 (%)
**5.5 Others - Market size and forecast 2020-2025
*Exhibit 28: Others - Market size and forecast 2020-2025 ($ million)
*Exhibit 29: Others - Year-over-year growth 2020-2025 (%)
**5.6 Market opportunity by Product
*Exhibit 30: Market opportunity by Product
***6. Customer landscape
**6.1 Overview
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
*Exhibit 31: ?Customer landscape?
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 32: Market share by geography 2020-2025 (%)
**7.2 Geographic comparison
*Exhibit 33: Geographic comparison
**7.3 North America - Market size and forecast 2020-2025
*Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
*Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
**7.4 Europe - Market size and forecast 2020-2025
*Exhibit 36: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 37: Europe - Year-over-year growth 2020-2025 (%)
**7.5 Europe - Market size and forecast 2020-2025
*Exhibit 38: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 39: Europe - Year-over-year growth 2020-2025 (%)
**7.6 ROW - Market size and forecast 2020-2025
*Exhibit 40: ROW - Market size and forecast 2020-2025 ($ million)
*Exhibit 41: ROW - Year-over-year growth 2020-2025 (%)
**7.7 Key leading countries
*Exhibit 42: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 43: Market opportunity by geography
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Increasing prevalence of diabetic neuropathy
*8.1.2 New drug approvals and strong drug pipeline
*8.1.3 Rising awareness about diabetic neuropathy
**8.2 Market challenges
*8.2.1 High cost of treatment
*8.2.2 Side-effects of major drugs
*8.2.3 Reimbursement challenges
*Exhibit 44: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Development of topical patches for the treatment of diabetic neuropathy
*8.3.2 Development of digital tools for management of diabetic neuropathy
*8.3.3 Association between obesity and endocrine disorders
*8.3.4 Growing focus on emerging economies
***9. Vendor Landscape
**9.1 Overview
*Exhibit 45: Vendor landscape
*The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
**9.2 Landscape disruption
*Exhibit 46: ?Landscape disruption?
*Exhibit 47: Industry risks
**9.3 Competitive landscape
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 48: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 49: ?Market positioning of vendors?
**10.3 Alnylam Pharmaceuticals Inc.
*Exhibit 50: Alnylam Pharmaceuticals Inc. - Overview
*Exhibit 51: Alnylam Pharmaceuticals Inc. - Product and service
*Exhibit 52: Alnylam Pharmaceuticals Inc. - Key offerings
**10.4 Astellas Pharma Inc.
*Exhibit 53: Astellas Pharma Inc. - Overview
*Exhibit 54: Astellas Pharma Inc. - Product and service
*Exhibit 55: Astellas Pharma Inc. - Key offerings
**10.5 AstraZeneca Plc
*Exhibit 56: AstraZeneca Plc - Overview
*Exhibit 57: AstraZeneca Plc - Product and service
*Exhibit 58: AstraZeneca Plc - Key offerings
**10.6 Daiichi Sankyo Co. Ltd.
*Exhibit 59: Daiichi Sankyo Co. Ltd. - Overview
*Exhibit 60: Daiichi Sankyo Co. Ltd. - Business segments
*Exhibit 61: Daiichi Sankyo Co. Ltd. - Key offerings
*Exhibit 62: Daiichi Sankyo Co. Ltd. - Segment focus
**10.7 Eli Lilly and Co.
*Exhibit 63: Eli Lilly and Co. - Overview
*Exhibit 64: Eli Lilly and Co. - Business segments
*Exhibit 65: Eli Lilly and Co. - Key offerings
**10.8 Grunenthal GmbH
*Exhibit 66: Grunenthal GmbH - Overview
*Exhibit 67: Grunenthal GmbH - Product and service
*Exhibit 68: Grunenthal GmbH - Key offerings
**10.9 Johnson and Johnson Inc.
*Exhibit 69: Johnson and Johnson Inc. - Overview
*Exhibit 70: Johnson and Johnson Inc. - Business segments
*Exhibit 71: Johnson and Johnson Inc. - Key offerings
*Exhibit 72: Johnson and Johnson Inc. - Segment focus
**10.10 NeuroBo Pharmaceuticals Inc.
*Exhibit 73: NeuroBo Pharmaceuticals Inc. - Overview
*Exhibit 74: NeuroBo Pharmaceuticals Inc. - Product and service
*Exhibit 75: NeuroBo Pharmaceuticals Inc. - Key offerings
**10.11 Novartis AG
*Exhibit 76: Novartis AG - Overview
*Exhibit 77: Novartis AG - Business segments
*Exhibit 78: Novartis AG - Key offerings
*Exhibit 79: Novartis AG - Segment focus
**10.12 Pfizer Inc.
*Exhibit 80: Pfizer Inc. - Overview
*Exhibit 81: Pfizer Inc. - Business segments
*Exhibit 82: Pfizer Inc. - Key offerings
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 ????Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 83: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 84: ?Research Methodology
*Exhibit 85: ??Validation techniques employed for market sizing?
*Exhibit 86: ??Information sources
**11.4 List of abbreviations
*Exhibit 87: List of abbreviations
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.